

LISTING OF CLAIMS:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for ~~modulating~~ reducing an immune response in an animal by inhibiting an interaction between a dendritic cell and a T cell, comprising administering a compound which binds to a protein with the amino acid sequence of SEQ ID NO: 2 (DC-SIGN) on the surface of a dendritic cell, wherein said compound reduces one or more interactions between a dendritic cell and a T cell.

2. (canceled)

3. (original) The method of claim 1 wherein said animal is a mammal.

4. (original) The method of claim 3 wherein said mammal is a human.

5. (canceled)

6. (previously presented) The method of claim 1 wherein said compound reduces adhesion between DC-SIGN and an ICAM receptor on the surface of a T cell.

7. (original) The method of claim 6 wherein said ICAM receptor is selected from the group consisting of ICAM-2 receptors and ICAM-3 receptors.

8. (original) The method of claim 1 wherein said method i) induces tolerance, ii) is immunotherapeutic, iii) induces immunosuppression, iv) treats an autoimmune disease, or v) treats an allergy.

9. (previously presented) The method of claim 1 wherein said compound is selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, an antibiotic, a sugar, a protein, and an antibody.

10. (withdrawn) The method of claim 9 wherein said mannose carbohydrate is mannan or D-mannose.

11. (withdrawn) The method of claim 9 wherein said fucose carbohydrate is L-fucose.

12. (canceled)

13. (withdrawn) The method of claim 9 wherein said antibiotic is pradimicin A.

14. (withdrawn) The method of claim 9 wherein said sugar is selected from the group consisting of N-acetyl-D-glucosamine and galactose.

15. (withdrawn) The method of claim 9 wherein said protein is selected from the group consisting of gp120, analogs of gp120 and fragments of gp120.

Claims 16 - 18. (canceled)

19. (original) The method of claim 9 wherein said antibody is a monoclonal antibody.

Claims 20 - 22. (canceled)

23. (previously presented) The method of claim 9 wherein said antibody is selected from the group consisting of i) an antibody produced by hybridoma ECACC accession number 99040818 and ii) an antibody produced by hybridoma ECACC accession number 99040819.